ReviewNanomedicine (London, England)2025
Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
- Lipid-Polymer Nanoparticles (LiPoNs) Mediated Codelivery of AntimiR-21 and Gadolinium Chelate in Triple Negative Breast Cancer Theranostics.Bioengineering (Basel, Switzerland) · 2026Article
- Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.Breast cancer (Dove Medical Press) · 2026Review
- Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effect of Nano-Gefitinib on Solid Ehrlich Carcinoma via Targeting EGFR, RIPK2 Pathways, and Macrophage Reprogramming.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment.RSC advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the most prevalent and deadly cancers worldwide, affecting women. This review explores the potential of lipid-polymer hybrid nanoparticles (LPHNPs) as a next-generation drug delivery system for breast cancer therapy. The review categorizes LPHNPs and discusses their unique structure, preparation methods, and applications in cancer therapy. It delves into the various methods of preparing for LPHNPs. Furthermore, it examines the application of LPHNPs in treating various cancers, focusing on breast cancer, where they have shown promise in delivering single drugs, drug combinations, and nucleic acids like siRNA and miRNA. The ability of LPHNPs to overcome drug resistance and enhance therapeutic efficacy is emphasized, along with their potential for personalized medicine. The literature search was performed using PubMed, Scopus, and Web of Science databases to identify relevant studies published from 2009 to 2025. The review summarizes recent patents related to breast cancer treatment, showcasing advancements in drug delivery systems and therapeutic approaches. The conclusion underscores the transformative potential of LPHNPs in revolutionizing breast cancer treatment, provided that challenges in formulation, scalability, and long-term safety are addressed. Continued research and collaboration between researchers, clinicians, and regulatory bodies are essential to realize the benefits of LPHNPs in personalized cancer therapy. [Figure: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.